What are the main toxicities of proteasome inhibitor-based regimens?

Proteasome inhibitor-based regimens are a common treatment option for multiple myeloma and other hematological malignancies. However, these regimens are associated with several toxicities, including peripheral neuropathy, gastrointestinal side effects like diarrhea and nausea, thrombocytopenia, and an increased risk of infections. Additionally, proteasome inhibitors can also lead to cardiotoxicity, pulmonary toxicity, and liver dysfunction in some patients. Close monitoring and management of these toxicities are essential to ensure the safety and efficacy of proteasome inhibitor-based therapies.

This mind map was published on 17 May 2024 and has been viewed 107 times.